Arrowhead Research | ARWR - Employees Total Number

Stock Price
27.58
Daily Change
-1.50 -5.16%
Monthly
60.26%
Yearly
26.75%
Q3 Forecast
28.84

Arrowhead Research reported 609 in Employees for its fiscal year ending in September of 2024.



Financials
Stock Price USD
Assets USD 1.38B
Cash and Equivalent USD 129.79M
Current Assets USD 946.92M
Current Liabilities USD 194.53M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Employees 609
EPS Earnings Per Share USD -1.26
Equity Capital and Reserves USD 522.31M
Gross Profit on Sales USD 27.77M
Interest Expense on Debt USD 24.38M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Market Capitalization USD 3.51B
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Ordinary Share Capital USD 138.14M
PE Price to Earnings USD 436.79
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Selling and Administration Expenses USD 30.95M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Employees Change Date
Agios Pharmaceuticals 486 103 Dec/2024
Alnylam Pharmaceuticals 2.23K 130 Dec/2024
Arrowhead Research 609 84 Sep/2024
Incyte 2.62K 93 Dec/2024
Ionis Pharmaceuticals 1.07K 142 Dec/2024
Ligand Pharmaceuticals 68 10 Dec/2024
Merck 75K 3K Dec/2024
Moderna 5.8K 200 Dec/2024
Novartis USD 101.7K 2.62K Dec/2022
Sarepta Therapeutics 1.37K 58 Dec/2024
TG Therapeutics 338 74 Dec/2024
Ultragenyx Pharmaceutical 1.29K 18 Dec/2024
Vertex Pharmaceuticals 6.1K 700 Dec/2024
Xencor 250 30 Dec/2024